Purple Biotech (PPBT) Stock Price, News & Analysis

Company Overview

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.

Key Stats

• Today's Range: $0.72 to $0.92
• 50-Day Range: $0.78 to $2.78
• 52-Week Range: $0.71 to $13.95
• Volume: 47.09 million shs
• Average Volume: 55,634 shs
• Market Capitalization: $2.02 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $33.00
• Consensus Rating: Buy

Purple Biotech Stock Analysis - MarketRank™

Purple Biotech scored higher than 61% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Purple Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Purple Biotech has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Purple Biotech are expected to decrease in the coming year, from ($0.83) to ($1.65) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Purple Biotech is -1.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Purple Biotech is -1.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Purple Biotech has a P/B Ratio of 0.06. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.41% of the float of Purple Biotech has been sold short.

Short Interest Ratio / Days to Cover

Purple Biotech has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Purple Biotech has recently decreased by 34.77%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Purple Biotech does not currently pay a dividend.

Dividend Growth

Purple Biotech does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.41% of the float of Purple Biotech has been sold short.

Short Interest Ratio / Days to Cover

Purple Biotech has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Purple Biotech has recently decreased by 34.77%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.52

News Sentiment

Purple Biotech has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Purple Biotech this week, compared to 1 article on an average week.

Search Interest

5 people have searched for PPBT on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.

MarketBeat Follows

1 people have added Purple Biotech to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Purple Biotech insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.98% of the stock of Purple Biotech is held by insiders.

Percentage Held by Institutions

Only 9.64% of the stock of Purple Biotech is held by institutions.

PPBT Stock Analysis - Frequently Asked Questions

How have PPBT shares performed this year?

Purple Biotech's stock was trading at $4.69 at the start of the year. Since then, PPBT stock has decreased by 83.4% and is now trading at $0.78.

How were Purple Biotech's earnings last quarter?

Purple Biotech Ltd. Sponsored ADR (NASDAQ:PPBT) released its quarterly earnings results on Wednesday, August, 6th. The company reported ($0.40) EPS for the quarter, missing analysts' consensus estimates of ($0.21) by $0.19.

When did Purple Biotech's stock split?

Shares of Purple Biotech reverse split before market open on Tuesday, September 17th 2024.The 1-20 reverse split was announced on Friday, September 13th 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, September 17th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

How do I buy shares of Purple Biotech?

Shares of PPBT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Purple Biotech own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Purple Biotech investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Broadcom (AVGO), GE Aerospace (GE), Adobe (ADBE) and Catalyst Pharmaceuticals (CPRX).

Company Calendar

• Last Earnings: 8/06/2025
• Today: 9/04/2025
• Next Earnings (Estimated): 11/21/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PPBT
• Previous Symbol: NASDAQ:KTOV
• CIK: 1614744
• Web: www.kitovpharma.com
• Phone: (723) 933-3121
• Fax: 972-153-39333121
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Purple Biotech: $33.00
• High Price Target: $33.00
• Low Price Target: $33.00
• Potential Upside/Downside: +4,130.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.42)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$7.24 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -14.00%
• Return on Assets: -12.52%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.88
• Quick Ratio: 2.88

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $12.40 per share
• Price / Book: 0.06

Miscellaneous

• Outstanding Shares: 2,586,000
• Free Float: 2,509,000
• Market Cap: $2.02 million
• Optionable: Optionable
• Beta: 0.70